Company news
Co-Diagnostics, Inc. news in 2025
Co-Diagnostics, Inc.'s news releases, calls and decks from 2025, newest first.
Co-Diagnostics Announces Reverse Stock Split
December 30, 2025
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
December 29, 2025
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
December 18, 2025
Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation
December 17, 2025
Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025
December 9, 2025
Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India
December 8, 2025
Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health
November 20, 2025
Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA
November 18, 2025
Co-Diagnostics Reports Third Quarter 2025 Financial Results
November 13, 2025
Utah Governor Cox and BioUtah Recognize Co-Diagnostics Following Recent JV Announcement in Kingdom of Saudi Arabia
November 12, 2025
Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd
November 5, 2025
Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform
November 3, 2025
Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast
October 31, 2025
Co-Diagnostics to Host Fireside Chat on November 5th with CEO, Dwight Egan, to Discuss Recently Announced Definitive Agreement in Saudi Arabia
October 30, 2025
Co-Diagnostics, Inc. Announces Closing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
October 29, 2025
Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
October 28, 2025
Co-Diagnostics Signs Definitive Agreement with Arabian Eagle in the Kingdom of Saudi Arabia to Establish CoMira Diagnostics and Localize Co-Dx™ PCR Platform Across the Middle East
October 27, 2025
Co-Diagnostics Executive Leadership Team to Attend Global Health Exhibition 2025 in Riyadh, Saudi Arabia
October 22, 2025
Co-Diagnostics Announces Development of Proprietary Sample Prep Instrument for PoC Testing
October 16, 2025
Co-Diagnostics, Inc. to Attend 2025 Maxim Growth Summit
October 13, 2025
Co-Diagnostics, Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30
September 30, 2025
Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
September 18, 2025
Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
September 17, 2025
Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East
September 16, 2025
Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains
September 11, 2025
Co-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit
September 9, 2025
Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.
August 18, 2025
Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results
August 14, 2025
Co-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and Webcast
July 31, 2025
Co-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur on July 16-18, 2025
July 15, 2025
Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference
May 14, 2025
Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results
May 8, 2025
Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast
April 29, 2025
Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results
March 27, 2025
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast
March 13, 2025
Co-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit
March 6, 2025
Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025
March 3, 2025
Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance
February 21, 2025